Clinical utility of the risperidone formulations in the management of schizophrenia

University of Virginia Health System, Charlottesville, VA, USA.
Neuropsychiatric Disease and Treatment (Impact Factor: 2.15). 10/2011; 7:611-20. DOI: 10.2147/NDT.S14385
Source: PubMed

ABSTRACT Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prolactin (PRL) is a hormone produced in the anterior pituitary but also synthesized extra-pituitary where it can influence diverse cellular processes including inflammatory responses. Females experience greater pain in certain inflammatory conditions, but the contribution of the PRL system to sex-dependent inflammatory pain is unknown. We found that PRL regulates TRP channels in sex-dependent manner in sensory neurons. At >20ng/ml, PRL sensitizes TRPV1 in female, but not male neurons. This effect is mediated by PRL receptor (PRL-R). Likewise, TRPA1 and TRPM8 were sensitized by 100ng/ml PRL only in female neurons. We showed that complete Freund adjuvant (CFA) up-regulated PRL levels in the inflamed paw of both male and female rats, but levels were higher in females. In contrast, CFA did not change mRNA levels of long and short PRL-R in the dorsal root ganglion or spinal cord. Analysis of PRL and PRL-R KO mice demonstrated that basal responses to cold stimuli were only altered in females, and with no significant effects on heat and mechanical responses in both sexes. CFA-induced heat and cold hyperalgesia were not changed in PRL and PRL-R KO compared to WT males, while significant reduction of heat and cold post-CFA hyperalgesia was detected in PRL and PRL-R KO females. Attenuation of CFA-induced mechanical allodynia was observed in both PRL and PRL-R KO females and males. Thermal hyperalgesia in PRL KO females was restored by administration of PRL into hindpaws. Overall, we demonstrate a sex-dependent regulation of peripheral inflammatory hyperalgesia by the PRL system.
    AJP Endocrinology and Metabolism 09/2013; 305(9). DOI:10.1152/ajpendo.00187.2013 · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction. The aim of our study was to assess the effect of switching from long-acting injectable (LAI) risperidone to paliperidone palmitate (PP) on sexual function and prolactin levels in patients with psychosis. We carried out a prospective observational study during a 3-month period that involved 11 patients with psychosis treated with risperidone-LAI who suffered from hyperprolactinaemia and who were then switched to PP. Two assessments were completed: the first one before the switch and the second one 3 months after the switch. These assessments measured sexual function using the Arizona Sexual Experience Scale and assessed prolactin levels. Our results showed a significant decrease in serum prolactin levels (P=0.041). We observed a four-fold reduction in clinically significant sexual dysfunction that is suggestive of benefit, although the sample size is too small to be sure. Our study suggests that prolactin levels seem to decrease after switching from risperidone-LAI to PP in patients with a psychotic disorder.
    International clinical psychopharmacology 01/2013; 28(1):46-9. DOI:10.1097/YIC.0b013e32835ba832 · 3.10 Impact Factor
  • 05/2013; 15(3). DOI:10.4088/PCC.12l01454

Full-text (3 Sources)

Available from
Jun 4, 2014